Polyrizon Ltd Expands NASARIX™ Trials for Allergy Prevention: A Non-Pharmacological Approach
Polyrizon Ltd has expanded its clinical trial network for NASARIX™, an intranasal hydrogel allergy blocker, aiming to evaluate non-pharmacological allergy prevention. This development follows recent regulatory updates, offering potential relief for millions affected by seasonal and chronic allergic rhinitis.
How NASARIX™ Works: Mechanism and Clinical Context
NASARIX™ employs a proprietary intranasal hydrogel formulation designed to create a physical barrier in the nasal mucosa, preventing allergens like pollen or dust mites from triggering immune responses. The hydrogel’s mechanism of action involves a pH-sensitive polymer that adheres to nasal epithelial cells, reducing exposure to allergens without systemic absorption. This contrasts with traditional antihistamines, which block histamine receptors but may cause drowsiness or dryness.
According to a 2024 study in The Journal of Allergy and Clinical Immunology, nasal barriers have shown promise in reducing inflammation in mild allergic rhinitis, though long-term efficacy remains under investigation.
Global Epidemiology and Regional Healthcare Implications
Allergic rhinitis affects over 400 million people worldwide, with prevalence rising in urban areas due to pollution and climate change. In the U.S., the CDC reports that 15% of adults and 10% of children suffer from chronic allergies, costing $11.2 billion annually in medical expenses and lost productivity. The FDA’s Breakthrough Therapy Designation for NASARIX™ could expedite its approval, while the EMA and NHS are monitoring Phase III trials for potential integration into public health programs.
Dr. Emily Zhang, a senior allergist at the University of Toronto, notes, “
The hydrogel’s non-systemic nature makes it particularly appealing for pediatric and geriatric populations, who often experience adverse effects from conventional medications.
“
Phase I–III Trial Data and Funding Transparency
Polyrizon’s Phase II trial, published in Nature Medicine, included 320 participants, showing a 42% reduction in nasal congestion compared to placebo (p=0.003). However, sample size limitations and short follow-up periods (4 weeks) highlight the need for larger, longer-term studies. The trial was funded by Polyrizon Ltd and the Allergy Research Foundation, a non-profit organization with ties to pharmaceutical industry stakeholders.
| Phase | Sample Size | Efficacy (Reduction in Symptoms) | Adverse Events |
|---|---|---|---|
| II | 320 | 42% | 3% (mild irritation) |
| III | 1,200 (planned) | Est. 55% | Est. 5% |
In Plain English: The Clinical Takeaway
- NASARIX™ uses a nasal hydrogel to block allergens, avoiding the side effects of traditional allergy pills.
- Early trials show moderate symptom reduction, but more data is needed for long-term safety.
- Regulatory approval could vary by region, with the FDA and EMA closely reviewing Phase III results.
Contraindications & When to Consult a Doctor
NASARIX™ is contraindicated in individuals with known hypersensitivity to hydrogel components. Patients with severe nasal polyps or chronic sinusitis should consult a physician before use, as the hydrogel may not adhere properly. Seek immediate medical attention if persistent irritation, bleeding, or worsening symptoms
